Linagliptin(lin ah glip’ tin)
Tradjenta
PREGNANCY CATEGORY B
Drug Classes
Antidiabetic
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic Actions
Slows the inactivation of the incretin hormones by DPP-4, increasing these hormone levels and prolonging their activity. The incretin hormones stimulate insulin release in response to a meal and help regulate glucose homeostasis throughout the day. This action increases and prolongs insulin release and reduces hepatic glucose production to help achieve glycemic control.
Indications
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
NEW INDICATION: • As an adjunct to insulin, diet, and exercise to achieve glycemic control in type 2 diabetics
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to linagliptin.
Use cautiously with concurrent use of strong CYP3A inducers; pregnancy, lactation.
Available Forms
Tablets—5 mg
Dosages
Adults
5 mg PO once a day without regard to food.
Pediatric patients
Safety and efficacy not established.
